Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma By Ogkologos - October 5, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Sustainability a major focus of our 17th year partnering with TK... October 11, 2021 Black In Cancer – That Cancer Conversation October 8, 2021 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... EMA Recommends Granting a Marketing Authorisation for Inavolisib Women at High Risk of Breast Cancer Find it Hard to...
